Abstract
Tobacco smoking is one of the leading causes of preventable death. Management of tobacco smoking is comprehensive and multifaceted involving both non-pharmacological and pharmacological interventions. Various smoking cessation pharmacotherapies are currently available but are only modestly effective. Long-term abstinence rates with available therapies are typically 25–35%. Therefore new and effective aids are required. Varenicline is a novel drug acting as selective nicotinic receptor partial agonist. Several randomized, double blind clinical trials have demonstrated higher smoking cessation rates with varenicline compared to bupropion—an established anti-smoking agent. Relapse prevention effect has also been demonstrated in one of these studies. Overall, varenicline has good safety profile, the most common side effects being nausea (28%) and insomnia (21%). The novel mechanism of action, better efficacy and excellent tolerability make varenicline a promising therapeutic option for clinicians and smokers.
This is a preview of subscription content, log in via an institution to check access.
References
Doll, R., Peto, R., Boreham, J., & Sutherland, I. (2004). Mortality in relation to smoking: 50 years’ observations on male British doctors. British Medical Journal, 328, 1519. Retrieved December 19, 2006 from http://www.bmj.com/cgi/content/full/328/7455/1519.
Faessel, H. M., Smith, B. J., Gibbs, M. A., Gobey, J. S., Clark, D. J., & Burstein, A. H. (2006). Single-dose pharmacokinetics of varenicline, a selective nicotinic receptor partial agonist in healthy smokers and nonsmokers. Journal of Clinical Pharmacology, 46(9), 991–998.
Foulds, J. (2006). The neurobiological basis for partial agonist treatment of nicotine dependence: Varenicline. International Journal of Clinical Practice, 60(5), 571–576.
Gonzales, D., Rennard, S. I., Nides, M., Oncken, C., Azoulay, S., Billing, C. B., et al. (2006). Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation and a randomized controlled trial. Journal of the American Medical Association, 296, 47–55.
Hughes, J. R. (2007). Effects of abstinence from tobacco: Valid symptoms and time course. Nicotin & Tobacco Research, 9(3), 315–27.
Jorenby, D. E., Hays, J. T., Rigotti, N. A., Azoulay, S., Watsky, E. J., Williams, K. E., et al. (2006). Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation—a randomized controlled trial. Journal of the American Medical Association, 296, 56–63.
Lerman, C. (2006). Helping smokers quit through pharmacogenetics. LDI Issue Brief, 11(6), 1–4.
Obach, R. S., Reed-Hagen, A. E., Krueger, S. S., Obach, B. J., O’Connell, T. N., Zadi, S., et al. (2006). Metabolism and disposition of varenicline, a selective a4β2 acetylcholine receptor agonist, in vivo and in vitro. Drug Metabolism and Disposition, 34, 121–130.
Tonstad, S., Tønnesen, P., Hajek, P., Williams, K. E., Billing, C. B., & Reeves, K. R. (2006). Effect of maintenance therapy with varenicline on smoking cessation—a randomized controlled trial. Journal of the American Medical Association, 296, 64–71.
World Health Organization (1997). Tobacco or health: A global status report. Geneva, Switzerland: World Health Organization.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wardhan, N., Chopra, D. & Rehan, H.S. Varenicline: A Novel Drug for Smoking Cessation. Int J Ment Health Addiction 5, 244–247 (2007). https://doi.org/10.1007/s11469-007-9090-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11469-007-9090-8